# US 7,264,816 B2 · Virulent systemic feline calicivirus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,264,816 B2
- Document ID: US7264816B2
- Status: Granted
- Kind: B2
- Application number: 10/769,531
- Filed: 2004-01-30
- Published: 2004-12-23
- Granted: 2007-09-04
- Earliest claimed: 2003-03-14
- Assignees: The Regents of the University of California
- Inventors: Janet E. Foley; Kate Hurley; Niels C. Pedersen; Amy Poland
- Web page: https://patentgrep.com/patent/US7264816B2

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61K 39/125: Picornaviridae, e.g. calicivirus
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- C07K 14/005: from viruses
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2770/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/16061: Methods of inactivation or attenuation
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a vaccine for immunization against a viral infection caused by a virulent systemic feline calicivirus (VS-FCV), a novel, atypical and unusually virulent form of a calicivirus that results in a highly contagious and fatal hemorrhagic fever syndrome. The present invention further encompasses methods of immunizing cats against particular strains of VS-FCV.

## Claims

### Claim 1

An isolated virulent systemic calicivirus (VS-FCV), wherein said virus causes a highly contagious hemorrhagic fever syndrome in cats with symptoms selected from the group consisting of high fever, edema, ulceration, hair loss, nasal and ocular discharge, anorexia, depression, and death, wherein treatment of said cats with an immunologically effective dose of FCV-F9 achieves substantially no protection against infection with VS-FCV; and wherein said VS-FCV comprises a capsid protein including lysine at amino acid position 448; glutamic acid at amino acid position 452; and lysine or aspartic acid at amino acid position 581 when optimally aligned with the capsid protein of SEQ ID NO:1.

### Claim 2 (depends on 1)

An immunogenic composition for immunization against a viral infection caused by the VS-FCV of claim 1, wherein said immunogenic composition comprises an immunologically effective amount of said VS-FCV and a physiologically acceptable carrier.

### Claim 3 (depends on 2)

The immunogenic composition of claim 2, further comprising an adjuvant.

### Claim 4 (depends on 2)

The composition of claim 2, wherein said VS-FCV is killed.

### Claim 5 (depends on 2)

The composition of claim 2, wherein said VS-FCV is attenuated.

### Claim 6 (depends on 2)

The composition of claim 2, wherein said VS-FCV is partially inactivated.

### Claim 7 (depends on 1)

The isolated virulent systemic calicivirus (VS-FCV) of claim 1, wherein the capsid protein further comprises lysine at amino acid position 399; threonine is at amino acid position 430; valine at amino acid position 438; and wherein said VS-FCV further comprises a glycosylation site including an asparagine at amino acid position 394.

### Claim 8 (depends on 1)

The isolated virulent systemic calicivirus of claim 1, wherein the cap sid protein sequence is SEQ ID NO:2.

### Claim 9 (depends on 1)

The isolated virulent systemic calicivirus of claim 1, wherein the capsid protein sequence is SEQ ID NO:3.

### Claim 10 (depends on 1)

The isolated virulent systemic calicivirus of claim 1, wherein the capsid protein sequence is SEQ ID NO:4.